EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Hodgkin Lymphoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms. MAH: Merck Sharp & Dohme B.V.. Decision date: 30/03/2026